Extended-Release Drugs Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Extended-Release Drugs Market Size By 2025?
The market size for extended-release medications has seen swift expansion in recent times. The market worth is expected to escalate from $63.11 billion in 2024 to $70.28 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%. Factors contributing to the growth throughout the historical period include better adherence to treatment by patients, an increase in chronic diseases, enhanced effectiveness, strategies for patent protection, and the use of biodegradable implants.

How Big Is the Extended-Release Drugs Market Size Expected to Grow by 2029?
The market for extended-release medications is projected to rapidly expand in the coming years. The market is estimated to reach a value of $113.05 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.6%. This prospective growth within the forecast period can be credited to factors such as the implementation of personalized medicine strategies, patient-focused drug creation, increasing prevalence of lifestyle diseases, the repurposing of drugs, and worldwide accessibility to extended-release treatments. Key trends expected within this period involve pharmaceutical novelty, advancements in drug distribution systems and nanotechnology, the application of 3D printing in drug formulation, the employment of artificial intelligence, and considerations of environmental sustainability.

View the full report here:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Key Market Drivers Powering Extended-Release Drugs Market Expansion and Growth?
The rising prevalence of chronic illnesses is predicted to spur the expansion of the extended-release medication industry. Chronic diseases-those that persist for a year or more, necessitating ongoing medical treatment or limiting daily activities-are on the rise, with heart disease, cancer, obesity, and diabetes being among the notable examples. Extended-release drug delivery systems, which are designed to sustain a fairly steady medication level in the body over an extended period, are gaining popularity. This approach keeps the therapeutic effect consistent and prevents the volatility observed with immediate-release drugs. The National Center for Biotechnology Information (NCBI), a department of the US National Library of Medicine, indicated in January 2023 that by 2050, the population aged 50 and above with at least one chronic ailment would likely increase by 99.5%, amounting to 142.66 million. This amplifies the evidence that the escalating prevalence of chronic diseases is fuelling the growth of the extended-release drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Extended-Release Drugs Market?
In the arena of the extended-release drug market, one growing trend is product innovation. Key players in this market are introducing unique products in an attempt to solidify their market presence. An example is Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical manufacturer based in the US. In July 2022, they introduced their Topiramate extended-release capsules meant for epilepsy. Prior to this, the US Food and Drug Administration (USFDA) had granted the company the permission to sell Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg, making Zydus the first company in the country to receive this approval and release these types of capsules. They are designed and approved to treat individuals experiencing either partial onset seizures or primary generalized tonic-clinic seizures.

What Are the Emerging Segments in the Extended-Release Drugs Market?
The extended-release drugs market covered in this report is segmented -

1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp

Who Are the Global Leaders in the Extended-Release Drugs Market?
Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

Which are the Top Profitable Regional Markets for the Extended-Release Drugs Industry?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.